BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 10917363)

  • 1. Unexpected neurotoxicity of etoposide phosphate administered in combination with other chemotherapeutic agents after blood-brain barrier modification to enhance delivery, using propofol for general anesthesia, in a rat model.
    Fortin D; McCormick CI; Remsen LG; Nixon R; Neuwelt EA
    Neurosurgery; 2000 Jul; 47(1):199-207. PubMed ID: 10917363
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The influence of anesthetic choice, PaCO2, and other factors on osmotic blood-brain barrier disruption in rats with brain tumor xenografts.
    Remsen LG; Pagel MA; McCormick CI; Fiamengo SA; Sexton G; Neuwelt EA
    Anesth Analg; 1999 Mar; 88(3):559-67. PubMed ID: 10072006
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Decreased delivery and acute toxicity of cranial irradiation and chemotherapy given with osmotic blood-brain barrier disruption in a rodent model: the issue of sequence.
    Remsen LG; McCormick CI; Sexton G; Pearse HD; Garcia R; Neuwelt EA
    Clin Cancer Res; 1995 Jul; 1(7):731-9. PubMed ID: 9816039
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current status and future of relapsed primary central nervous system lymphoma (PCNSL).
    Tyson RM; Siegal T; Doolittle ND; Lacy C; Kraemer DF; Neutwelt EA
    Leuk Lymphoma; 2003 Apr; 44(4):627-33. PubMed ID: 12769339
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intra-arterial administration improves temozolomide delivery and efficacy in a model of intracerebral metastasis, but has unexpected brain toxicity.
    Muldoon LL; Pagel MA; Netto JP; Neuwelt EA
    J Neurooncol; 2016 Feb; 126(3):447-54. PubMed ID: 26694547
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Osmotic blood-brain barrier disruption chemotherapy for diffuse pontine gliomas.
    Hall WA; Doolittle ND; Daman M; Bruns PK; Muldoon L; Fortin D; Neuwelt EA
    J Neurooncol; 2006 May; 77(3):279-84. PubMed ID: 16314949
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intraarterial chemotherapy and osmotic blood-brain barrier disruption for patients with embryonal and germ cell tumors of the central nervous system.
    Jahnke K; Kraemer DF; Knight KR; Fortin D; Bell S; Doolittle ND; Muldoon LL; Neuwelt EA
    Cancer; 2008 Feb; 112(3):581-8. PubMed ID: 18072268
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term toxicity and neuropathology associated with the sequencing of cranial irradiation and enhanced chemotherapy delivery.
    Remsen LG; McCormick CI; Sexton G; Pearse HD; Garcia R; Mass M; Roman-Goldstein S; Neuwelt EA
    Neurosurgery; 1997 May; 40(5):1034-40; discussion 1040-2. PubMed ID: 9149262
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The potential for complete and durable response in nonglial primary brain tumors in children and young adults with enhanced chemotherapy delivery.
    Dahlborg SA; Petrillo A; Crossen JR; Roman-Goldstein S; Doolittle ND; Fuller KH; Neuwelt EA
    Cancer J Sci Am; 1998; 4(2):110-24. PubMed ID: 9532413
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improving drug delivery to intracerebral tumor and surrounding brain in a rodent model: a comparison of osmotic versus bradykinin modification of the blood-brain and/or blood-tumor barriers.
    Kroll RA; Pagel MA; Muldoon LL; Roman-Goldstein S; Fiamengo SA; Neuwelt EA
    Neurosurgery; 1998 Oct; 43(4):879-86; discussion 886-9. PubMed ID: 9766316
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Toxicity and efficacy of carboplatin and etoposide in conjunction with disruption of the blood-brain tumor barrier in the treatment of intracranial neoplasms.
    Williams PC; Henner WD; Roman-Goldstein S; Dahlborg SA; Brummett RE; Tableman M; Dana BW; Neuwelt EA
    Neurosurgery; 1995 Jul; 37(1):17-27; discussion 27-8. PubMed ID: 8587686
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intra-arterial chemotherapy with osmotic blood-brain barrier disruption for aggressive oligodendroglial tumors: results of a phase I study.
    Guillaume DJ; Doolittle ND; Gahramanov S; Hedrick NA; Delashaw JB; Neuwelt EA
    Neurosurgery; 2010 Jan; 66(1):48-58; discussion 58. PubMed ID: 20023537
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rat model of blood-brain barrier disruption to allow targeted neurovascular therapeutics.
    Martin JA; Maris AS; Ehtesham M; Singer RJ
    J Vis Exp; 2012 Nov; (69):e50019. PubMed ID: 23222697
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multiple sessions of liposomal doxorubicin delivery via focused ultrasound mediated blood-brain barrier disruption: a safety study.
    Aryal M; Vykhodtseva N; Zhang YZ; McDannold N
    J Control Release; 2015 Apr; 204():60-9. PubMed ID: 25724272
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhanced chemotherapy delivery by intraarterial infusion and blood-brain barrier disruption in the treatment of cerebral metastasis.
    Fortin D; Gendron C; Boudrias M; Garant MP
    Cancer; 2007 Feb; 109(4):751-60. PubMed ID: 17211866
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential permeability of a human brain tumor xenograft in the nude rat: impact of tumor size and method of administration on optimizing delivery of biologically diverse agents.
    Neuwelt EA; Barnett PA; McCormick CI; Remsen LG; Kroll RA; Sexton G
    Clin Cancer Res; 1998 Jun; 4(6):1549-55. PubMed ID: 9626476
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Primary meningeal CNS lymphoma treated with intra-arterial chemotherapy and blood-brain barrier disruption.
    Macnealy MW; Newton HB; McGregor JM; Bell SD; Ray Chaudhury A; Slone HW; Bourekas EC
    J Neurooncol; 2008 Dec; 90(3):329-33. PubMed ID: 18758913
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Seizure-promoting effect of blood-brain barrier disruption.
    Marchi N; Angelov L; Masaryk T; Fazio V; Granata T; Hernandez N; Hallene K; Diglaw T; Franic L; Najm I; Janigro D
    Epilepsia; 2007 Apr; 48(4):732-42. PubMed ID: 17319915
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Imaging and therapy with rituximab anti-CD20 immunotherapy in an animal model of central nervous system lymphoma.
    Muldoon LL; Lewin SJ; Dósa E; Kraemer DF; Pagel MA; Doolittle ND; Neuwelt EA
    Clin Cancer Res; 2011 Apr; 17(8):2207-15. PubMed ID: 21385922
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Osmotic blood-brain barrier modification for the treatment of malignant brain tumors.
    Haluska M; Anthony ML
    Clin J Oncol Nurs; 2004 Jun; 8(3):263-7. PubMed ID: 15208820
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.